Shanghai Institute of Material Medical Chinese Academy of Sciences

Biography

Dr. HE Yong joined Dr. GAO Bin’s laboratory of liver diseases at National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institutes of Health (NIH) in 2014 as a joint PhD student of Graduate Partnerships Program between NIH and Anhui Medical University. After receiving PhD degree in 2016, Dr He continued his postdoctoral studies at NIH and was offered an NIH full-time Equivalent Employment (FTE) research position in 2019. In the past several years, Dr. He has been actively investigating the immunological aspects and molecular pathogenesis of liver diseases including acute liver injury, alcoholic liver disease, nonalcoholic steatohepatitis, liver fibrosis and HCC, focusing on the roles of microRNAs and cytokines in the progression of liver diseases. Dr. He has more than 25 peer-reviewed publications in prestigious journals such as Journal of Clinical Investigation, Journal of Hepatology, Gut, Hepatology, and Cell Mol Immunol.

Education

2013.09 - 2016.06 Anhui Medical University, Ph.D

2010.09 - 2013.06 Anhui Medical University, MS

2006.09 - 2010.06 Anhui Medical University, BD

Work Experience

2021.06 - Now Professor, Principal Investigator Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China

2019.07 - 2021.05 Research Fellow, National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institutes of Health (NIH), USA

2016.07 - 2019.06 Postdoctoral Fellow, National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institutes of Health (NIH), USA

Research Directions

1. the immunological aspects and molecular pathogenesis of liver diseases;

2. hepatic inflammation, injury and immunity in liver diseases;

3. novel therapeutic targets of alcoholic and nonalcoholic liver diseases (nonalcoholic steatohepatitis).

Grants & Research Projects

Achievements

1. Identifying neutrophil-specific microRNA-223 as a great therapeutic target for the treatment of various types of liver diseases including alcoholic and nonalcoholic fatty liver diseases, drug-induced liver injury and liver fibrosis.

2. Firstly providing novel pathobiological and mechanistic insights into the role of IL-20 in the promotion of acute hepatitis and bacterial infection.

morefold

Social Titles

morefold

Awards & Honors

1. 2015 FARE (Fellows Award for Research Excellence) 2016 Award, National Institutes of Health (NIH)

2. 2016 Shanghai Wu Mengchao Medical Science Foundation International Cooperation &Communication Special Fund

3. 2016 FARE (Fellows Award for Research Excellence) 2017 Award, National Institutes of Health (NIH)

4. 2019 FARE (Fellows Award for Research Excellence) 2020 Award, National Institutes of Health (NIH)

morefold

Pubilcations

Full Publication List

Selected Publications

(#co-first authors, *corresponding authors)

1.He, Y.*, D. Feng, S. Hwang, B. Mackowiak, X. Wang, X. Xiang, R.M. Rodrigues, Y. Fu, J. Ma, T. Ren, Y. Ait-Ahmed, M. Xu, S. Liangpunsakul, B. Gao*. Interleukin-20 exacerbates acute hepatitis and bacterial infection by downregulating IκBζ target genes in hepatocytes. J Hepatol. 2021; 75(1):163-176. (Featured by an editorial: Pedro M Rodrigues et al. J Hepatol. 2021;75(1): 22-24)

2.He. Y., R. Rodrigues, X. Wang, W. Seo, J. Ma, S. Hwang, Y. Fu, E. Trojnár, C. Mátyás, S. Zhao, R. Ren, D. Feng, P. Pacher, G. Kunos, B. Gao*. Neutrophil-to-hepatocyte communication via LDLR-dependent miR-223-enriched extracellular vesicle transfer ameliorates nonalcoholic steatohepatitis. J Clin Invest. 2021; 131(3): e141513.

3.He, Y., S. Hwang, Y. Cai, S. J. Kim, M. Xu, D. Yang, A. Guillot, D. Feng, W. Seo, X. Hou and B. Gao*. MicroRNA-223 Ameliorates Nonalcoholic Steatohepatitis and Cancer by Targeting Multiple Inflammatory and Oncogenic Genes in Hepatocytes. Hepatology, 2019 70(4): 1150-1167.

4.He, Y., D. Feng, M. Li, Y. Gao, T. Ramirez, H. Cao, S. J. Kim, Y. Yang, Y. Cai, C. Ju, H. Wang, J. Li* and B. Gao*. Hepatic mitochondrial DNA/Toll-like receptor 9/MicroRNA-223 forms a negative feedback loop to limit neutrophil overactivation and acetaminophen hepatotoxicity in mice. Hepatology, 2017 66(1): 220-234.

5.Wang, X., W. Seo, S.H. Park, Y. Fu, S. Hwang, R.M. Rodrigues, D. Feng, B. Gao*, Y. He*. MicroRNA-223 restricts liver fibrosis by inhibiting the TAZ-IHH-GLI2 and PDGF signaling pathways via the crosstalk of multiple liver cell types. Int J Biol Sci. 2021;17(4):1153-1167.

6.He, Y#., S. Hwang#, Y. A. Ahmed, D. Feng, N. Li, M. Ribeiro, F. Lafdil, T. Kisseleva, G. Szabo and B. Gao*. Immunopathobiology and therapeutic targets related to cytokines in liver diseases. Cell Mol Immunol, 2021;18(1):18-37.

morefold